{"id":14410,"date":"2012-11-07T09:40:20","date_gmt":"2012-11-07T08:40:20","guid":{"rendered":"http:\/\/miunidad.eu\/porib.com\/?p=14410"},"modified":"2021-09-22T09:42:07","modified_gmt":"2021-09-22T07:42:07","slug":"betegon-l-guilloteau-i-martin-p-woolmore-a-oyaguez-i","status":"publish","type":"post","link":"https:\/\/porib.com\/en\/betegon-l-guilloteau-i-martin-p-woolmore-a-oyaguez-i\/","title":{"rendered":"Betegon L, Guilloteau I, Martin P, Woolmore A, Oyag\u00fcez  I"},"content":{"rendered":"<div class=\"col80\">\n<p class=\"miniatura_foto\" style=\"text-align: justify;\"><strong><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-14157 alignleft\" src=\"https:\/\/porib.com\/wp-content\/uploads\/2021\/09\/ISPOR.jpg\" alt=\"\" width=\"120\" height=\"120\" \/>Betegon L, Guilloteau I, Martin P, Woolmore A, Oyag\u00fcez I<\/strong><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<div class=\"col80p\">\n<h6 style=\"text-align: justify;\">The relative value of dasatinib versus imatinib as first-line treatment for chronic myeloid leukemiay<\/h6>\n<h6 style=\"text-align: justify;\"><strong>15th Annual European Congress International Society for Pharmacoeconomics &amp; Outcomes Research (ISPOR). Berlin, Germany. 3-7 nov 2012<\/strong><\/h6>\n<p><a href=\"https:\/\/porib.com\/wp-content\/uploads\/2021\/09\/104.pdf\" target=\"_blank\" rel=\"noopener\">POSTER<\/a><\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Betegon L, Guilloteau I, Martin P, Woolmore A, Oyag\u00fcez I &nbsp; &nbsp; The relative value of dasatinib versus imatinib as first-line treatment for chronic myeloid leukemiay 15th Annual European Congress International Society for Pharmacoeconomics &amp; Outcomes Research (ISPOR). Berlin, Germany. 3-7 nov 2012 POSTER<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"quote","meta":{"footnotes":""},"categories":[937,933,246],"tags":[],"class_list":["post-14410","post","type-post","status-publish","format-quote","hentry","category-amc-ac-tipo-de-proyecto","category-hematologia-oncohematologia","category-international-society-of-pharmacoeconomics-and-outcomes-research","post_format-post-format-quote"],"translation":{"provider":"WPGlobus","version":"2.10.3","language":"en","enabled_languages":["es","en"],"languages":{"es":{"title":true,"content":true,"excerpt":false},"en":{"title":false,"content":false,"excerpt":false}}},"_links":{"self":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/14410"}],"collection":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/comments?post=14410"}],"version-history":[{"count":1,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/14410\/revisions"}],"predecessor-version":[{"id":14412,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/14410\/revisions\/14412"}],"wp:attachment":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/media?parent=14410"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/categories?post=14410"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/tags?post=14410"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}